IGF-IR targeted therapy: Past, present and future

Frontiers in Endocrinology

Volumn 5, Issue DEC, 2014, Pages

  Janssen, Joseph A M J L ^a   Varewijck, Aimee J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Hyperglycemia; IGF I receptor; IGF IR antibodies; IGF IR targeted therapy; Insulin receptor A; Insulin receptor B

Indexed keywords

ADAPTOR PROTEIN; G PROTEIN COUPLED RECEPTOR; GROWTH HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CELL GROWTH; CELL PROLIFERATION; DNA REPAIR; DOWN REGULATION; GENE ACTIVATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; PROTEIN PROCESSING; SEQUENCE ANALYSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 84920165976     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00224     Document Type: Short Survey

References (64)

1. Clemmons DR. Targeting the insulin-like growth factor-I receptor in cancer therapy. In: Leroith D, editor. Insulin-Like Growth Factors and Cancer: From Basic Biology to Therapeutics. New York, NY: Springer (2012). p. 193-213.
2. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 63:317-32. doi: 10.1159/000066230
3. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 3:509-17. doi:10.1210/mend-3-3-509
4. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res (2003) 13:113-70. doi:10.1016/S1096-6374(03)00038-8
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 16:3-34. doi:10.1210/edrv-16-1-3
6. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology (1980) 107:1176-81. doi:10.1210/endo-107-4-1176
7. Wang HS, Wang TH. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med J (2003) 26:540-53.
8. King ER, Wong KK. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov (2012) 7:14-30. doi:10.2174/157489212798357930
9. Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer (2012) 19:F63-75. doi:10.1530/ERC-12-0026
10. Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell (1985) 40:747-58. doi:10.1016/0092-8674(85)90334-4
11. Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A (1989) 86:114-8. doi:10.1073/pnas.86.1.114
12. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol (1989) 3:1263-9. doi:10.1210/mend-3-8-1263
13. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19:3278-88.
14. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 30:586-623. doi:10.1210/er.2008-0047
15. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev (2008) 19:111-20. doi:10.1016/j.cytogfr.2008.01.005
16. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, Mcclain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J (1990) 9:2409-13.
17. Mosthaf L, Vogt B, Haring HU, Ullrich A. Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus patients. Proc Natl Acad Sci U S A (1991) 88:4728-30. doi:10.1073/pnas.88.11.4728
18. Sesti G, Marini MA, Tullio AN, Montemurro A, Borboni P, Fusco A, et al. Altered expression of the two naturally occurring human insulin receptor variants in isolated adipocytes of non-insulin-dependent diabetes mellitus patients. Biochem Biophys Res Commun (1991) 181:1419-24. doi:10.1016/0006-291X(91)92097-4
19. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab (2000) 278:E967-76.
20. Rechler MM, Clemmons DR. Regulatory actions of insulin-like growth factor-binding proteins. Trends Endocrinol Metab (1998) 9:176-83. doi:10.1016/S1043-2760(98)00047-2
21. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J (1997) 327(Pt 1):209-15.
22. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 277:39684-95. doi:10.1074/jbc. M202766200
23. Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, Mathiasen IS, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem (2006) 281:25869-74. doi:10.1074/jbc. M605189200
24. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 12(Suppl 1):S99-111. doi:10.1677/erc.1.01005
25. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 65:1849-57. doi:10.1158/0008-5472.CAN-04-1837
26. Xu J, Messina JL. Crosstalk between growth hormone and insulin signaling. Vitam Horm (2009) 80:125-53. doi:10.1016/S0083-6729(08)00606-7
27. Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, et al. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology (2014) 155:1207-21. doi:10.1210/en.2013-1925
28. Coppola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R, et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol (1994) 14:4588-95.
29. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res (2006) 66:10100-11. doi:10.1158/0008-5472.CAN-06-1684
30. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 118:2609-19. doi:10.1172/JCI34588
31. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets (2009) 9:748-60. doi:10.2174/156800909789271495
32. Groenendijk FH, Bernards R. Drug resistance to targeted therapies: Deja vu all over again. Mol Oncol (2014) 8(6):1067-83. doi:10.1016/j.molonc.2014.05.004
33. Chen HX, Sharon E. IGF-1R as an anti-cancer target - trials and tribulations. Chin J Cancer (2013) 32:242-52. doi:10.5732/cjc.012.10263
34. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res (2003) 63:627-35.
35. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 12:159-69. doi:10.1038/nrc3215
36. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene (2009) 28:3009-21. doi:10.1038/onc.2009.172
37. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 40(9):1096-105. doi:10.1016/j.ctrv.2014.07.004
38. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 27:2516-22. doi:10.1200/JCO.2008.19.9331
39. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2010) 11:129-35. doi:10.1016/S1470-2045(09)70354-7
40. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 17:6304-12. doi:10.1158/1078-0432.CCR-10-3336
41. Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 4:30. doi:10.3389/fphar.2013.00030
42. Girnita L, Worrall C, Takahashi S, Seregard S, Girnita A. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2014) 71:2403-27. doi:10.1007/s00018-013-1514-y
43. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 63:8912-21.
44. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res (2005) 11:2063-73. doi:10.1158/1078-0432.CCR-04-1070
45. Weinstein D, Sarfstein R, Laron Z, Werner H. Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells. Endocr Connect (2014) 3:24-35. doi:10.1530/EC-13-0086
46. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res (2007) 67:391-7. doi:10.1158/0008-5472.CAN-06-1712
47. Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol (2013) 228:675-9. doi:10.1002/jcp.24217
48. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Koornstra RH, Linn SC, Oyen WJ, et al. Dynamics of IGF-1R expression during endocrine breast cancer treatment. Mol Imaging Biol (2014) 16:529-37. doi:10.1007/s11307-014-0723-6
49. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, et al. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One (2012) 7:e33322. doi:10.1371/journal.pone.0033322
50. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer (2012) 48:3027-35. doi:10.1016/j.ejca.2012.05.009
51. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell (2010) 141:1117-34. doi:10.1016/j.cell.2010.06.011
52. Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 10:2437-48. doi:10.1158/1535-7163.MCT-11-0235
53. Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y. Igf-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev (2011) 7:235-45. doi:10.2174/157339911796397848
54. Janssen JA, Varewijck AJ. Insulin analogs and cancer: a note of caution. Front Endocrinol (2014) 5:79. doi:10.3389/fendo.2014.00079
55. Baricevic I, Roberts DL, Renehan AG. Chronic insulin exposure does not cause insulin resistance but is associated with chemo-resistance in colon cancer cells. Horm Metab Res (2014) 46:85-93. doi:10.1055/s-0033-1354414
56. Perry JK, Liu DX, Wu ZS, Zhu T, Lobie PE. Growth hormone and cancer: an update on progress. Curr Opin Endocrinol Diabetes Obes (2013) 20:307-13. doi:10.1097/MED.0b013e328363183a
57. Xu JW, Wang TX, You L, Zheng LF, Shu H, Zhang TP, et al. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. PLoS One (2014) 9:e92847. doi:10.1371/journal.pone.0092847
58. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer (2007) 109:170-9. doi:10.1002/cncr.22402
59. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 14:6364-70. doi:10.1158/1078-0432.CCR-07-4879
60. Varewijck AJ, Brugts MP, Frystyk J, Goudzwaard JA, Uitterlinden P, Waaijers AM, et al. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. Mol Cell Endocrinol (2013) 365:17-24. doi:10.1016/j.mce.2012.08.021
61. Davies PC, Lineweaver CH. Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Phys Biol (2011) 8:015001. doi:10.1088/1478-3975/8/1/015001
62. Fleuren ED, Versleijen-Jonkers YM, Heskamp S, Van Herpen CM, Oyen WJ, Van Der Graaf WT, et al. Theranostic applications of antibodies in oncology. Mol Oncol (2014) 8:799-812. doi:10.1016/j.molonc.2014.03.010
63. Fleuren ED, Versleijen-Jonkers YM, Van De Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res (2011) 17:7693-703. doi:10.1158/1078-0432.CCR-11-1488
64. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther (2012) 11:2644-53. doi:10.1158/1535-7163.MCT-12-0447